InvestorsHub Logo
Followers 62
Posts 2098
Boards Moderated 0
Alias Born 05/09/2020

Re: 3X Charm post# 91423

Monday, 07/06/2020 11:43:53 PM

Monday, July 06, 2020 11:43:53 PM

Post# of 232290
I did some public research into the payments that CytoDyn made to Samsung Biologics.

These are unverified numbers and only my estimations. If anyone knows differently please chime in.

CytoDyn made a $31M payment to Samsung to secure production of enough Leronlimab to fill 1.2m vials.
(http://www.koreabiomed.com/news/articleView.html?idxno=5857)

I think makes it about $25/vial that CytoDyn paid.

NP said in his interview with DRBEEN that the price outside the US is very negotiable. The price inside the USA "was set by Gilead when they set the price of Remdesivir."

I think there's a lot of wiggle room on pricing here. Plus there are two CMO (contract manufacturing organization) that CytoDyn has under contract and are fully capable and certified by the FDA to produce Leronlimab - Samsung Biologics and AGC Biologics. Both have enormous capacity to produce. Samsung Biologics alone can produce 360,000 liters/year. I think that works out to 120,000,000 vials per year (each vial 3ml)


Just based on Samsung's manufacturing capacity:

My math....I hope my metric math is correct here....
So.... 1 Leronlimab dose = 3ml or .003L


360,000L / 3ml = 120 million doses
-or-
360,000L / 0.003L = 120 million doses (wow...that's a lot)

120,000,000 doses / 4 doses = 30,000,000 patients
Average of 4 doses per patient treatment



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News